Abbott Laboratories (US) and F. Hoffmann-La Roche (Switzerland) are Leadng Players in the Immunoassay Market
The global immunoassay market is projected to reach USD 46.7 billion by 2028 from USD 35.0 billion in 2023, at a CAGR of 5.9% during the forecast period. The immunoassay market is driven by the rising prevalence of infectious diseases, coupled with supportive government policies for the early detection of these diseases.
The top players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Thermo Fisher Scientific, Inc. (US). These players hold leading positions in the market owing to their broad product offerings in the immunoassay market. These mentioned players have undertaken various organic and inorganic growth strategies such as product launches and approvals, collaborations, acquisitions, and agreements to retain their position in the market.
To know about the assumptions considered for the study download the pdf brochure
Abbott Laboratories (US) accounted for the largest share of nearly 20–25% in 2022. Abbott has a strong presence in the North American region and seeks to further strengthen its geographical presence by establishing its business operations in emerging markets. The company has a strong product portfolio, and its FDA- and CE Mark-approved products have helped it maintain its market presence.
F. Hoffmann-La Roche (Switzerland) held the second position in the immunoassay market in 2022. The company’s vast product portfolio, including tissue diagnostic instruments, clinical chemistry and immunochemistry solutions, molecular diagnostic products, reagents, and kits, is the primary factor for its significant share in the market. Under its flagship brand, cobas, the company offers various IVD instruments, reagents, and kits. The company mainly focuses on product launches and approvals, which has helped it gain a more extensive customer base across major regions such as North America, Europe, Asia Pacific, and the Middle East.
Thermo Fisher Scientrific, Inc. (US) held the third largest share of 6.0-8.0% of the immunoassay market in 2022. The company operates geographically in more than 50 countries across North America, Europe, Latin America, and Asia. The company’s focus on product development and launches helps it to maintain its market position. In June 2022, Thermo Scientific received FDA approval for its B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers, the immunoassays used for the risk assessment and clinical management of preeclampsia. While in May 2022, Thermo Fisher launched the Phadia 2500+ Instrument family in the US for autoimmune testing.
Related Reports:
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
